Abstract 383: Efficacy of immune checkpoint inhibitors in lung cancer patients with EGFR P719A mutation: A case report

Background: Results from previous studies indicated that lung cancer patients harboring EGFR sensitizing mutations may receive unfavorable outcomes from immunotherapy. The present study aims to investigate the efficacy of inhibitors of programmed cell death protein-1in lung cancer patients with driver oncogene EGFR P719A mutations and strong positive PD-L1 expression in one special case. Methods: Tissue samples were subjected to NGS in our College of American Pathologists-certified and Clinical Laboratory Improvement Amendments-accredited lab for driver oncogene mutations and PD-L1 expression. Results: A 52-year-old male never-smoker who complained of a persistent cough was examined by computed tomography (CT), which revealed a 39 mm wide tumor in the upper region of the right lobe of the lung in May 2019. Tumor biopsy pathology revealed that the patient had a stage IIIB (T2N3M0) adenocarcinoma. NGS performed on a formalin-fixed, paraffin-embedded tumor specimen to identify genomic aberrations. The tumor was positive for EGFR, EGFR P719A mutation. The PD-L1 expression have been tested by FDA-approved 22C3 antibodies, and PD-L1 expression level of 95%. The patients received anti-PD-1 combination treatment. He has reached partial response (PR) after 4 cycle treatment. After ten months, he has the opportunity to receive the operation. The following anti-PD-1/L1 monotherapy is still ongoing until now. Conclusion: Our real-world study supported that NSCLC patients harboring sensitizing oncogenic mutations may potentially benefit from anti-PD-1/L1 especially for those with positive indicators of immunotherapy with strong positive PD-L1 expression. Citation Format: Fuyu Gong, Kai Zheng. Efficacy of immune checkpoint inhibitors in lung cancer patients with EGFR P719A mutation: A case report [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 383.